Other languages Lundbeck Nasdaq Copenhagen

Equities

LUN

DK0061804697

Market Closed - Nasdaq Copenhagen Other stock markets 10:59:37 2024-05-08 am EDT			5-day change	1st Jan Change
29.5 ^DKK	+0.34%		+2.08%	-14.59%

Apr. 09	H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy	MT
Apr. 09	Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy	Apr. 09
Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD	Apr. 09
EU Commission Green-lights Lundbeck, Otsuka's Abilify Maintena as Maintenance Treatment of Schizophrenia	Mar. 27
Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia	Mar. 27
H. Lundbeck A/S Announces Management Appointments	Mar. 20
H. Lundbeck A/S Approves Dividend for the Accounting Year 2023	Mar. 20
H. Lundbeck Plans Clinical Development of Migraine Prevention Drug	Mar. 15
H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage	Mar. 15
H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023	Feb. 23
H. Lundbeck A/S Announces Changes to Executive Management	Feb. 23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW